Thromboembolism in multiple myeloma patients receiving thalidomide combination chemotherapy.

被引：0
|
作者：
Wrigh, A. [1 ]
Elkins, S. [1 ]
Files, J. [1 ]
Bigelow, C. [1 ]
Herrin, V. [1 ]
Sample, M. [1 ]
机构：
[1] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA
来源：
JOURNAL OF INVESTIGATIVE MEDICINE | 2007年 / 55卷 / 01期
关键词：
D O I：
10.1097/00042871-200701010-00839
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S302 / S302
页数：1
相关论文
共 50 条
  • [1] Venous Thromboembolism Prophylaxis with Aspirin for Multiple Myeloma Patients Receiving Thalidomide Combination As First-Line Treatment
    Crusoe, Edvan de Queiroz
    Massarenti, Mariana
    Almeida, Manuella
    Cury, Priscilla
    Higashi, Fabiana
    Vieira, Luiza
    Rossato, Marina
    Peres, Ana Lucia
    Castro, Anna Carolina
    Silva, Ana Luiza
    Hungria, Vania T. M.
    BLOOD, 2014, 124 (21)
  • [2] Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy.
    Alexanian, R
    Weber, DM
    Giralt, S
    Delasalle, KB
    BLOOD, 2001, 98 (11) : 163A - 163A
  • [3] Incidence of renal impairment (RI) in multiple myeloma (MM) patients receiving combination chemotherapy and thalidomide (Thal) with bisphosphonate therapy.
    Latif, T
    Elson, P
    Karam, MA
    Reed, J
    Tahir, K
    Srkalovic, G
    Hussein, MA
    BLOOD, 2003, 102 (11) : 687A - 687A
  • [4] Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
    Zangari, M
    Anaissie, E
    Barlogie, B
    Badros, A
    Desikan, R
    Gopal, AV
    Morris, C
    Toor, A
    Siegel, E
    Fink, L
    Tricot, G
    BLOOD, 2001, 98 (05) : 1614 - 1615
  • [5] Incidence of thromboembolism in korean multiple myeloma patients with thalidomide induction chemotherapy; comparison previous data in Korea
    Ha, H.
    Youk, J.
    Park, H.
    Lee, J-O
    Bang, S-M
    Kim, K-H
    Park, J-H
    Koh, Y.
    Kim, I
    Yoon, S-S
    Park, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 990 - 991
  • [6] Low incidence of deep venous thrombosis in poor prognosis multiple myeloma patients treated with thalidomide and CED chemotherapy.
    Moehler, TM
    Schlenzka, J
    Kasper, B
    Neben, K
    Egerer, G
    Ho, AD
    Goldschmidt, H
    BLOOD, 2002, 100 (11) : 393B - 393B
  • [7] Hypothyroidism in patients with multiple myeloma (MM) receiving thalidomide.
    Badros, A
    Zangari, M
    Bodenner, D
    Siegel, E
    Spoon, D
    Toor, A
    Desikan, R
    Arnold, E
    Anaissie, E
    Zeldis, J
    Tricot, G
    Barlogie, B
    BLOOD, 2000, 96 (11) : 285B - 285B
  • [8] A systematic review of the incidence of venous thromboembolism (VTE) and effectiveness of prophylaxis in patients with multiple myeloma (MM) receiving thalidomide
    Wu, C. M.
    Lee, A. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Low incidence of thromboembolism in Korean patients with multiple myeloma treated with thalidomide
    Koh, Y.
    Bang, S.
    Lee, J.
    Yoon, H.
    Do, Y.
    Ryoo, H.
    Lee, N.
    Kim, S.
    Kim, K.
    Kim, H.
    Yoon, S.
    Won, J.
    Mun, Y.
    Lee, M.
    Rhee, K.
    Eom, H.
    Kim, M.
    Shin, H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1100 - 1101
  • [10] Erythropoietin therapy and venous thromboembolic events in patients with multiple myeloma receiving chemotherapy with or without thalidomide.
    Zangari, Maurizio
    Cavallo, Federica
    Prasad, Keshava
    Fink, Louis
    Coon, Sharon
    Barlogie, Bart
    Tricot, Guido
    BLOOD, 2006, 108 (11) : 1020A - 1020A
12345